Cambridge, MA, June 16,2016 - The Harvard Stem Cell Institute, three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for...

Giant step toward new diabetes treatment

Harvard stem cell researchers today announced that they have made a giant leap forward in the quest to find a truly...

When the organizers of the upcoming World Regenerative Medicine Congress recently asked scientists and executives across the world in the stem cell and regenerative medicine fields to name “the most influential people in the global stem cell and cell therapy field,” two of HSCI’s leaders were in the top 11.

Doug Melton, HSCI’s Co-Director and Co-Founder, was named number five on the list of the world’s top 50 “Stem Cell Influencers.”  Melton, who is also co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, was cited as “one of the driving forces behind...

A portfolio of small molecules and biologics has been licensed by Harvard University and the Howard Hughes Medical Institute from the laboratory of Harvard Stem Cell Institute Co-Director Doug Melton, co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, to the German biotech firm Evotec and international giant Janssen Pharmaceuticals, a Johnson & Johnson company, as the central focus of a new program to pursue treatments and cures for diabetes.

“Our collaboration with Doug Melton’s laboratory has been extremely successful on multiple levels,” said Evotec...